As emerging therapies move through the clinical pipeline, scale and regulatory compliance have come to the forefront of the discussion. A fully automated process that addresses digital connectivity and instrument-to-instrument compatibility can help overcome some of the current cell therapy manufacturing challenges, increase the quality of the final product, as well as reduce manufacturing failure rates.
- The time and cost-saving advantages of implementing a fully automated manufacturing workflow
- The importance of digital connectivity solutions to ensure process and data integrity
- Considerations and benefits of a closed, modular cell therapy workflow
